EG 427 is unlocking the full potential of gene therapy for the treatment of localized severe chronic diseases. Overcoming current in vivo gene therapy vectors limitations, EG427 has built a non-replicative Herpes Simplex Virus 1 (HSV-1) platform, to ensure safe and highly selective delivery of large transgenes. Thanks to its natural lifelong latency in peripheral neurons, its non-replicative redosable vector platform offers a durable expression to treat, in the long run, patients with severe, chronic, and localized diseases, starting with peripheral nervous system disorders. With an IND slated for early 2024, we will be the next company, to have a non-replicative herpes-based construct in human clinical trial, and the first one to address sensory neuron-based pathologies.